All stock lists
ADMA Biologics Inc (NASDAQ:ADMA)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
13.18+2.69 (+25.72%)
Market cap
$2.95B
Insider Score
Health Score
Analyst consensus
Listed since
Oct 17, 2013
Website
Insider Score
––Not scored
ADMA Insider Score
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
Financial Health Score
Strong
From ADMA’s reported statements · Q3 2026 (trailing 12 months)
Profitability20 / 20
Keeps a healthy share of every dollar it sells.
- Revenue
- $519.2M
- Net income
- $182.4M
- Net margin
- 35.1%
Leverage18 / 20
Little or no net debt.
- Total debt
- $202.8M
- Cash
- $124.6M
- Net debt / EBITDA
- 0.31x
Liquidity20 / 20
Comfortably covers what is due within a year.
- Current assets
- $575.9M
- Current liabilities
- $95.3M
- Current ratio
- 6.04
Cash generation20 / 20
The business funds itself from operations.
- Operating cash flow
- $140.8M
- Free cash flow
- $132.9M
- FCF margin
- 25.6%
Dilution & runway20 / 20
Not funding itself by issuing shares.
- Shares outstanding
- 223.7M
- Share growth (1y)
- -6.2%
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
ADMA Income Statement
| Fiscal Period | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 |
| Revenue | 141.10 M | 124.39 M | 114.49 M | 139.16 M | 134.22 M | 121.98 M |
| Revenue Growth (YoY) | 5.12 % | 1.98 % | -0.27 % | 18.39 % | 12.00 % | 13.80 % |
| Cost of Revenue | 41.19 M | 38.12 M | 33.74 M | 50.35 M | 58.60 M | 54.76 M |
| Gross Profit | 99.92 M | 86.28 M | 80.75 M | 88.82 M | 75.63 M | 67.23 M |
| SG&A Expense | 26.55 M | 26.74 M | 26.74 M | 23.51 M | 23.05 M | 22.21 M |
| R&D Expense | 4.49 M | 6.01 M | 2.60 M | 1.38 M | 1.53 M | 1.03 M |
| Operating Expenses | 32.16 M | 33.83 M | 30.40 M | 26.07 M | 24.61 M | 24.43 M |
| Operating Income | 67.76 M | 52.45 M | 50.29 M | 62.75 M | 51.01 M | 42.80 M |
| Pretax Income | 65.60 M | 50.24 M | 57.13 M | 61.59 M | 47.52 M | 40.10 M |
| Tax Provision | 15.72 M | 12.41 M | 11.80 M | 12.22 M | 11.09 M | 5.88 M |
| Net Income | 49.88 M | 37.82 M | 45.33 M | 49.38 M | 36.43 M | 34.22 M |
| EPS (Basic) | 0.22 | 0.17 | 0.19 | 0.21 | 0.15 | 0.14 |
| EPS (Diluted) | 0.22 | 0.16 | 0.19 | 0.20 | 0.15 | 0.14 |
| Shares Outstanding | 223.70 M | 228.23 M | 236.07 M | 237.97 M | 238.60 M | 241.49 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.